Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation

Andreas Zuckermann, Nicolas Manito, Eric Epailly, Arnt Fiane, Christoph Bara, Juan F. Delgado, Hans Lehmkuhl, Heather Ross, Howard Eisen, Jeremy Chapman, Hannah Valantine

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Proliferation signal or mammalian target-of-rapamycin inhibitors (PSI/mTOR inhibitors), everolimus and sirolimus, provide attractive options for use in heart transplantation because they are immunosuppressive and anti-proliferative. PSI/mTOR inhibitors work synergistically with calcineurin inhibitors (CNIs) and thus permit the minimization of CNIs without compromising efficacy. This approach is advantageous for the majority of heart transplant recipients and might provide particular benefit in specific cases, such as patients with cardiac allograft vasculopathy, malignancies and renal dysfunction, or in patients intolerant to other immunosuppressive agents. Drawing on the expertise of transplant cardiologists, cardiac surgeons and nephrologists, we addressed the assessment of renal function; management of adverse events associated with this class of drugs; and clinical guidance, specifically for the use of everolimus, including patient selection, indications for treatment and practicalities of drug initiation and monitoring.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalJournal of Heart and Lung Transplantation
Volume27
Issue number2
DOIs
StatePublished - Feb 1 2008

Fingerprint

Sirolimus
Heart Transplantation
Immunosuppressive Agents
Patient Selection
Kidney
Drug Monitoring
Allografts
Transplants
Pharmaceutical Preparations
Neoplasms
Everolimus
Calcineurin Inhibitors

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

Zuckermann, Andreas ; Manito, Nicolas ; Epailly, Eric ; Fiane, Arnt ; Bara, Christoph ; Delgado, Juan F. ; Lehmkuhl, Hans ; Ross, Heather ; Eisen, Howard ; Chapman, Jeremy ; Valantine, Hannah. / Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation. In: Journal of Heart and Lung Transplantation. 2008 ; Vol. 27, No. 2. pp. 141-149.
@article{8c807dcd883244f0b206454b16eae437,
title = "Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation",
abstract = "Proliferation signal or mammalian target-of-rapamycin inhibitors (PSI/mTOR inhibitors), everolimus and sirolimus, provide attractive options for use in heart transplantation because they are immunosuppressive and anti-proliferative. PSI/mTOR inhibitors work synergistically with calcineurin inhibitors (CNIs) and thus permit the minimization of CNIs without compromising efficacy. This approach is advantageous for the majority of heart transplant recipients and might provide particular benefit in specific cases, such as patients with cardiac allograft vasculopathy, malignancies and renal dysfunction, or in patients intolerant to other immunosuppressive agents. Drawing on the expertise of transplant cardiologists, cardiac surgeons and nephrologists, we addressed the assessment of renal function; management of adverse events associated with this class of drugs; and clinical guidance, specifically for the use of everolimus, including patient selection, indications for treatment and practicalities of drug initiation and monitoring.",
author = "Andreas Zuckermann and Nicolas Manito and Eric Epailly and Arnt Fiane and Christoph Bara and Delgado, {Juan F.} and Hans Lehmkuhl and Heather Ross and Howard Eisen and Jeremy Chapman and Hannah Valantine",
year = "2008",
month = "2",
day = "1",
doi = "10.1016/j.healun.2007.08.014",
language = "English (US)",
volume = "27",
pages = "141--149",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "2",

}

Zuckermann, A, Manito, N, Epailly, E, Fiane, A, Bara, C, Delgado, JF, Lehmkuhl, H, Ross, H, Eisen, H, Chapman, J & Valantine, H 2008, 'Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation', Journal of Heart and Lung Transplantation, vol. 27, no. 2, pp. 141-149. https://doi.org/10.1016/j.healun.2007.08.014

Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation. / Zuckermann, Andreas; Manito, Nicolas; Epailly, Eric; Fiane, Arnt; Bara, Christoph; Delgado, Juan F.; Lehmkuhl, Hans; Ross, Heather; Eisen, Howard; Chapman, Jeremy; Valantine, Hannah.

In: Journal of Heart and Lung Transplantation, Vol. 27, No. 2, 01.02.2008, p. 141-149.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation

AU - Zuckermann, Andreas

AU - Manito, Nicolas

AU - Epailly, Eric

AU - Fiane, Arnt

AU - Bara, Christoph

AU - Delgado, Juan F.

AU - Lehmkuhl, Hans

AU - Ross, Heather

AU - Eisen, Howard

AU - Chapman, Jeremy

AU - Valantine, Hannah

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Proliferation signal or mammalian target-of-rapamycin inhibitors (PSI/mTOR inhibitors), everolimus and sirolimus, provide attractive options for use in heart transplantation because they are immunosuppressive and anti-proliferative. PSI/mTOR inhibitors work synergistically with calcineurin inhibitors (CNIs) and thus permit the minimization of CNIs without compromising efficacy. This approach is advantageous for the majority of heart transplant recipients and might provide particular benefit in specific cases, such as patients with cardiac allograft vasculopathy, malignancies and renal dysfunction, or in patients intolerant to other immunosuppressive agents. Drawing on the expertise of transplant cardiologists, cardiac surgeons and nephrologists, we addressed the assessment of renal function; management of adverse events associated with this class of drugs; and clinical guidance, specifically for the use of everolimus, including patient selection, indications for treatment and practicalities of drug initiation and monitoring.

AB - Proliferation signal or mammalian target-of-rapamycin inhibitors (PSI/mTOR inhibitors), everolimus and sirolimus, provide attractive options for use in heart transplantation because they are immunosuppressive and anti-proliferative. PSI/mTOR inhibitors work synergistically with calcineurin inhibitors (CNIs) and thus permit the minimization of CNIs without compromising efficacy. This approach is advantageous for the majority of heart transplant recipients and might provide particular benefit in specific cases, such as patients with cardiac allograft vasculopathy, malignancies and renal dysfunction, or in patients intolerant to other immunosuppressive agents. Drawing on the expertise of transplant cardiologists, cardiac surgeons and nephrologists, we addressed the assessment of renal function; management of adverse events associated with this class of drugs; and clinical guidance, specifically for the use of everolimus, including patient selection, indications for treatment and practicalities of drug initiation and monitoring.

UR - http://www.scopus.com/inward/record.url?scp=38949125143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949125143&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2007.08.014

DO - 10.1016/j.healun.2007.08.014

M3 - Article

VL - 27

SP - 141

EP - 149

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 2

ER -